Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks ...

Blue Shield of California has cut the price it will pay for a biosimilar of the drug Humira. Blue Shield will purchase the medicine used to treat certain autoimmune and inflammatory diseases, such as ...